From Yale University School of Medicine, New Haven, CT (J.V.F., J.A., N.D., H.K.); Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, CT (J.V.F., Y.W., J.A., N.D., H.K.); and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA (Y.W.).
Circulation. 2017 Mar 28;135(13):1227-1239. doi: 10.1161/CIRCULATIONAHA.116.022388. Epub 2017 Feb 1.
Data are lacking on national trends for atrial fibrillation (AF) hospitalization, particularly with regard to long-term outcomes including readmission and mortality.
We studied all Medicare fee-for-service beneficiaries between 1999 and 2013, and we evaluated rates of hospitalization for AF, in-hospital mortality, length of stay, and hospital payments. We then evaluated rates of long-term outcomes, including 30-day readmission, 30-day mortality, and 1-year mortality. To evaluate changes in rates of AF hospitalization and mortality, we used mixed-effects models, adjusting for age, sex, race, and comorbidity. To assess changes in rates of 30-day readmission, we constructed a Cox proportional hazards model adjusting for age, sex, race, and comorbidity.
Adjusted rates of hospitalization for AF increased by ≈1% per year between 1999 and 2013, and although geographic variation was present, this trend was consistent nationwide. Median hospital length of stay remained unchanged at 3.0 (interquartile range 2.0-5.0) days, but median Medicare inpatient expenditure per beneficiary increased from $2932 (interquartile range $2232-$3870) to $4719 (interquartile range $3124-$7209) per stay. During the same period, the rate of inpatient mortality during AF hospitalization decreased by 4% per year, and the rate of 30-day readmission decreased by 1% per year. The rates of 30-day and 1-year mortality decreased more modestly by 0.4% and 0.26% per year, respectively.
Between 1999 and 2013, among Medicare fee-for-service beneficiaries, patients were hospitalized more frequently and treated with more costly inpatient therapies such as AF catheter ablation, but this finding was associated with improved outcomes, including lower rates of in-hospital mortality, 30-day readmission, 30-day mortality, and 1-year mortality.
缺乏关于房颤(AF)住院的全国趋势的数据,特别是关于包括再入院和死亡率在内的长期结果。
我们研究了 1999 年至 2013 年期间所有的 Medicare 按服务收费受益人和我们评估了 AF 住院率、住院死亡率、住院时间和医院支付。然后,我们评估了包括 30 天再入院率、30 天死亡率和 1 年死亡率在内的长期结果。为了评估 AF 住院率和死亡率的变化,我们使用了混合效应模型,调整了年龄、性别、种族和合并症。为了评估 30 天再入院率的变化,我们构建了 Cox 比例风险模型,调整了年龄、性别、种族和合并症。
1999 年至 2013 年间,AF 住院率每年增加约 1%,尽管存在地域差异,但这一趋势在全国范围内是一致的。中位数住院时间保持不变,为 3.0 天(四分位距 2.0-5.0),但每位受益人的医疗保险住院支出中位数从 2932 美元(四分位距 2232-3870 美元)增加到 4719 美元(四分位距 3124-7209 美元)/次。同期,AF 住院期间的住院死亡率每年下降 4%,30 天再入院率每年下降 1%。30 天和 1 年死亡率的下降幅度较小,分别为每年 0.4%和 0.26%。
1999 年至 2013 年期间,在 Medicare 按服务收费受益人中,患者住院频率更高,接受了更昂贵的住院治疗,如房颤导管消融术,但这一发现与更好的结果相关,包括更低的住院死亡率、30 天再入院率、30 天死亡率和 1 年死亡率。